Akoya Biosciences Inc
NASDAQ:AKYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Akoya Biosciences Inc
Revenue
Akoya Biosciences Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Akoya Biosciences Inc
NASDAQ:AKYA
|
Revenue
$81.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Revenue
$45.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Revenue
$24.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
|
|
Waters Corp
NYSE:WAT
|
Revenue
$3.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Revenue
$7.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Revenue
$16.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
Akoya Biosciences Inc
Glance View
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 319 full-time employees. The company went IPO on 2021-04-16. The firm deliveries spatial biology solutions, which is focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through its PhenoCycler and PhenoImager platform, reagents, software and services, it offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research. The company provides PhenoImager HT, which is a digital pathology slide scanner featuring MOTiF whole-slide multispectral scanning of up to seven biomarkers with an 80-slide capacity. The company offers contract research services laboratory, which is called as advanced biopharma solutions.
See Also
What is Akoya Biosciences Inc's Revenue?
Revenue
81.7m
USD
Based on the financial report for Dec 31, 2024, Akoya Biosciences Inc's Revenue amounts to 81.7m USD.
What is Akoya Biosciences Inc's Revenue growth rate?
Revenue CAGR 5Y
14%
Over the last year, the Revenue growth was -15%. The average annual Revenue growth rates for Akoya Biosciences Inc have been 14% over the past three years , 14% over the past five years .